Sunday, June 5, 2022
Hilton Chicago | Continental C
Registration & Dinner: 6:30 pm – 7:00 pm CDT
Scientific Session: 7:00 pm – 9:00 pm CDT

Learning Objectives

• Explain disparities in cancer outcomes and care among diverse patient populations;
• Evaluate strategies to broaden oncology clinical trial opportunities and enrollment among diverse populations;
• Analyze gaps in the screening, diagnosis, treatment selection, and access to care in diverse populations with cancer;
• Identify strategies to overcome disparities in diagnosis, testing, and treatment for patients with cancer.

Sunday, June 5, 2022
Hilton Chicago | Continental A
Registration & Dinner: 6:30 pm – 7:00 pm CDT
Scientific Session: 7:00 pm – 9:00 pm CDT

Learning Objectives

• Assess optimal molecular testing strategies for patients with NSCLC and EGFR exon 20 insertions along the continuum of care
• Describe the role of multidisciplinary team members in the delivery of care for patients with NSCLC and EGFR exon 20 insertions
• Apply safety and efficacy results from clinical trials assessing targeted approaches for the management of patients with advanced NSCLC and EGFR exon 20 insertions
• Summarize approaches to mitigate and manage treatment-related adverse events associated with the use of targeted therapy in patients with NSCLC and EGFR exon 20 insertions

Sunday, June 5, 2022
Hilton Chicago | Continental B
Registration & Dinner: 6:30 pm – 7:00 pm CDT
Scientific Session: 7:00 pm – 9:00 pm CDT

Learning Objectives

• Determine factors that inform care plans for patients with MF and PV based on genetics, risk stratification, and symptom burden
• Explain the mechanistic rationale for the application of therapeutic approaches for the management of MPNs
• Describe evidence from investigations on treatment approaches for MF and PV, including how these findings can inform proactive strategies planning to manage treatment-related toxicities
• Devise strategies to integrate emerging evidence to manage clinical scenarios commonly encountered in the care of patients with MPNs along the disease continuum

Friday, June 3, 2022
Hyatt Regency | Plaza Ballroom
Registration and Dinner: 6:00 - 6:30 PM CDT
Scientific Session: 6:30 PM - 8:30 PM CDT

Learning Objectives

• Discuss the role of multidisciplinary team members in addressing barriers to testing and the interpretation of molecular test results for patients with early stage and metastatic NSCLC
• Summarize high-risk genomic co-mutations that occur in patients with EGFR mutation–positive NSCLC
• Assess outcomes among EGFR mutation profiles with the application of different EGFR inhibitor-based monotherapy and combination regimens
• Apply approaches to mitigate and manage treatment-related toxicities associated with the use of targeted therapy in patients with early-stage and metastatic NSCLC

Friday, June 3, 2022
Hilton Chicago | Continental A
Registration & Dinner: 6:30 pm – 7:00 pm CDT
Scientific Session: 7:00 pm – 9:00 pm CDT

Learning Objectives

• Determine actionable biomarkers to inform decision-making in the management of advanced NSCLC
• Explain the role of testing and ways to facilitate diagnosis for NSCLC treatment
• Describe efficacy and safety of investigations that used actionable biomarkers to personalize NSCLC care
• Evaluate emerging targets and biomarker-driven strategies undergoing late-stage evaluation for use in advanced NSCLC

Friday, June 3, 2022
Hilton Chicago | Continental B
Registration & Dinner: 6:30 pm – 7:00 pm CDT
Scientific Session: 7:00 pm – 9:00 pm CDT

Learning Objectives

• Determine DLBCL subtypes, biomarkers, and risk assessment methods, and how these factors inform treatment strategies for patients with relapsed/refractory (R/R) disease
• Evaluate the clinical profiles of current and emerging targeted therapies investigated for the treatment of R/R DLBCL
• Implement strategies to monitor and mitigate the impact of adverse events associated with targeted therapies among patients with R/R DLBCL
• Translate treatment guidelines and landmark trial data on targeted therapies to personalize sequencing strategies for patients with R/R DLBCL

Friday, June 3, 2022
Hilton Chicago | International Ballroom South
Registration & Dinner: 6:30 pm – 7:00 pm CDT
Scientific Session: 7:00 pm – 9:00 pm CDT

Learning Objectives

• Assess recent clinical trial evidence concerning the safety and efficacy of immunotherapy used as single-agents or combination strategies for melanoma management
• Evaluate the efficacy and safety of targeted therapies, including BRAF/MEK inhibition, in the management of melanoma
• Describe treatment-related adverse events and appropriate management strategies for patients with melanoma
• Utilize approaches to optimize clinical decision-making across multiple lines of care in melanoma

Friday, June 3, 2022
Hilton Chicago | Continental C
Registration & Dinner: 6:30 pm – 7:00 pm CDT
Scientific Session: 7:00 pm – 9:00 pm CDT

Learning Objectives

• Evaluate the rationale for using genetic testing strategies in managing endometrial cancer through biomarker-based decision-making
• Summarize key results of clinical trials involving emerging treatments and combinations of therapy in patients with endometrial cancer, as guided by biomarkers and genomic data
• Describe relevant supportive measures in timely detection and management of potential treatment-related adverse events with therapies for endometrial cancer
• Explain the most efficient uses of biomarker-based therapy along with other relevant evaluation strategies to formulate personalized treatment plans

Saturday, June 4, 2022
Hilton Chicago | Continental A
Registration & Dinner: 6:30 pm – 7:00 pm CDT
Scientific Session: 7:00 pm – 9:00 pm CDT

Learning Objectives

• Describe efficacy and safety data of next-generation SERD agents for the management of HR+/HER2- breast cancer
• Explain how patient and tumoral characteristics can be aligned with clinical trial evidence to inform decision-making in the management of HR+/HER2- breast cancer
• Apply recent trial evidence to manage case scenarios typically encountered in HR+/HER2- breast cancer care and in consideration of evolving treatment paradigms in the field
• Determine ongoing trials concerning SERDs that are intended to address clinical gaps in the field of HR+/HER2- breast cancer management

Saturday, June 4, 2022
Hilton Chicago | Continental C
Registration & Dinner: 6:30 pm – 7:00 pm CDT
Scientific Session: 7:00 pm – 9:00 pm CDT

Learning Objectives:

• Outline key features of liquid biopsies and how they differ from conventional biopsies in the diagnosis and monitoring of cancer
• Explain evidence concerning the reliability of existing and emerging liquid biopsy technologies in cancer care
• Evaluate the relevance of multiple forms of liquid biopsy in the biomarker-driven management of multiple common and less common cancer types
• Summarize the latest evidence concerning the use of liquid biopsy and best practices for real-world applications of these tests

Saturday, June 4, 2022
Hilton Chicago | Continental B
Registration & Dinner: 6:30 pm – 7:00 pm CDT
Scientific Session: 7:00 pm – 9:00 pm CDT

Learning objectives:

• Explain the criteria for MDS diagnosis, as well as available tools for its classification and risk stratification
• Review endpoints utilized in recent clinical trials that have changed treatment of high-risk MDS
• Discuss unmet clinical needs in patients with high-risk MDS and the rationale for emerging therapies and combination strategies in patients with MDS
• Report the efficacy and safety profiles for current and emerging approaches for the care of patients with higher-risk MDS

Saturday, June 4, 2022
Hilton Chicago | International Ballroom South
Registration & Dinner: 6:30 pm – 7:00 pm CDT
Scientific Session: 7:00 pm – 9:00 pm CDT

Learning Objectives

• Explain clinical trial data and evidence-based recommendations for the management of nonmetastatic and metastatic forms of CRPC
• Optimize sequencing of current therapies
• Assess trial evidence on novel approaches to CRPC and their impact on evolving treatment paradigms
• Monitor and manage treatment-associated toxicities